Trevor Resnick, MD, an epileptologist with special qualifications in pediatric neurology at the Nicklaus Children's Hospital, gives an overview of CBD oil and its efficacy for patients with Lennox-Gastaut syndrome and Dravet syndrome.
Transcript
Trevor Resnick, MD: Cannabinoid oil is a derivative of cannabis, and we don't really know the mechanism of action for canniboid oil. It may be linked to the g-receptor protein or the -- we don't know. Nevertheless, it has been demonstrated to be effective in patients with Lennox-Gastaut syndrome and in patients with Dravet syndrome. And it's actually approved for seizures associated with those two syndromes. And, I think it's approved for above 2-years of age. And the effectiveness of cannabinoid oil was gratifying in those 2 syndromes, and it's approved for those 2 syndromes.
And the major side-effects are fatigue, sleepiness, diaherra. And another, not specifically a side-effect, but it does have interaction with some medications that are commonly used for both those syndromes.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.